Benzinga | Mar 2, 2021 08:01AM EST

Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $40

Morgan Stanley analyst Matthew Harrison maintains Editas Medicine (NASDAQ:EDIT) with a Underweight and lowers the price target from $45 to $40.